Arrowhead Accelerates Capital Contribution to Insert Therapeutics as Nanotech Cancer Drug Heads toward Human Clinical Trials.
Business Wire › October 11, 2005
Linked as:
Extract
Arrowhead Accelerates Capital Contribution to Insert Therapeutics as Nanotech Cancer Drug Heads toward Human Clinical Trials.
PASADENA, Calif. -- Arrowhead Research Corp. (Nasdaq:ARWR), a diversified nanotechnology company providing the missing link between lab and marketplace, has accelerated its investment of an additional $3 million to majority-owned subsidiary Insert...
See the full content of this document
Sponsored links
